Evidence map›Paper›PMID 35242131›Full record

ArticleFrontiers in immunology2022

Case Report: Cytomegalovirus Disease Is an Under-Recognized Contributor to Morbidity and Mortality in Common Variable Immunodeficiency.

Samantha Chan, Jack Godsell, Miles Horton, Anthony Farchione, Lauren J Howson, Mai Margetts, Celina Jin, Josh Chatelier, Michelle Yong, Joseph Sasadeusz and 3 more

Registry-linked trialOpen access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06574789 (Individualised Dose Optimisation of Ganciclovir in Immunocompromised Children Trial), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06574789 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

Individualised Dose Optimisation of Ganciclovir in Immunocompromised Children Trial (ID-MAGIC)

TypeinterventionalSponsorMurdoch Childrens Research InstituteRan2024 to 2028Enrolled232ConditionsCytomegalovirus ViraemiaArmsStandard dosing of IV ganciclovir, Personalised dosing of IV ganciclovir
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Review
  5. Cytomegalovirus drives Vδ1Nature communications · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Samantha ChanImmunology Division, Walter & Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Jack GodsellDepartment of Clinical Immunology & Allergy, Royal Melbourne Hospital, Melbourne, VIC, Australia.
Miles HortonImmunology Division, Walter & Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Anthony FarchioneImmunology Division, Walter & Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Lauren J HowsonImmunology Division, Walter & Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Mai MargettsImmunology Division, Walter & Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Celina JinImmunology Division, Walter & Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Josh ChatelierDepartment of Clinical Immunology & Allergy, Royal Melbourne Hospital, Melbourne, VIC, Australia.
Michelle YongVictorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, VIC, Australia.
Joseph SasadeuszVictorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, VIC, Australia.
Jo A DouglassDepartment of Clinical Immunology & Allergy, Royal Melbourne Hospital, Melbourne, VIC, Australia.
Charlotte A SladeImmunology Division, Walter & Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
Vanessa L BryantImmunology Division, Walter & Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
The Royal Melbourne Hospital · AUWalter and Eliza Hall Institute of Medical Research · AUUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCommon Variable Immunodeficiency (CVID) is classified as a 'Predominantly Antibody Deficiency' (PAD), but there is emerging evidence of cellular immunodeficiency in a subset of patients. This evidence includes CVID patients diagnosed with cytomegalovirus (CMV) infection, a hallmark of 'combined immunodeficiency'. CMV infection also has the potential to drive immune dysregulation contributing to significant morbidity and mortality in CVID. We aim to determine the extent of cellular immune dysfunction in CVID patients, and whether this correlates with CMV infection status.

methodsWe conducted a single-center retrospective cohort study of individuals with CVID at the Royal Melbourne Hospital, and identified patients with and without CMV disease or viraemia. We then isolated T-cells from patient and healthy donor blood samples and examined T-cell proliferation and function.

resultsSix patients (7.6%, 6/79) had either CMV disease (pneumonitis or gastrointestinal disease), or symptomatic CMV viraemia. A high mortality rate in the cohort of patients with CVID and CMV disease was observed, with 4 deaths in the period of analysis (66.6%, 4/6). Individuals with CMV infection showed reduced T-cell division in response to T-cell receptor (TCR) stimulation when compared with CMV-negative patients. DISCUSSION: This study demonstrates the morbidity and mortality associated with CMV in CVID, and highlights the need for focused interventions for patients with CVID at risk of CMV disease.

Indexed as

Common Variable ImmunodeficiencyCytomegalovirus InfectionsPrimary Immunodeficiency DiseasesCytomegalovirusHumansMorbidityRetrospective StudiesViremiacellular immunitycommon variable immunodeficiencycytomegalovirusherpesvirus 6immunogeneticspredominantly antibody deficiencyprimary immunodeficiencies

Identifiers

PMID35242131
PMCPMC8885594
OpenAlexW4212778985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.